Chemoimmunotherapy Combos Solidified as Frontline Standard in Nonsquamous NSCLC
Published: Friday, May 03, 2019
Claude Denham, MD
The rationale for frontline chemoimmunotherapy in stage IV nonsquamous non–small cell lung cancer (NSCLC), now made evident by several phase III trials, stems from its synergistic activity, stimulatory effects on neoantigens, and tolerable safety profile.
... to read the full story